Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) EBITDA: 2019-2025

Historic EBITDA for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$111.9 million.

  • Beam Therapeutics' EBITDA fell 19.35% to -$111.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$415.6 million, marking a year-over-year decrease of 197.27%. This contributed to the annual value of -$376.7 million for FY2024, which is 190.88% down from last year.
  • Per Beam Therapeutics' latest filing, its EBITDA stood at -$111.9 million for Q3 2025, which was down 9.28% from -$102.4 million recorded in Q2 2025.
  • Beam Therapeutics' EBITDA's 5-year high stood at $145.4 million during Q4 2023, with a 5-year trough of -$201.6 million in Q1 2021.
  • For the 3-year period, Beam Therapeutics' EBITDA averaged around -$75.5 million, with its median value being -$94.8 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 554.08% in 2021, then spiked by 502.78% in 2023.
  • Beam Therapeutics' EBITDA (Quarterly) stood at -$64.8 million in 2021, then skyrocketed by 44.26% to -$36.1 million in 2022, then spiked by 502.78% to $145.4 million in 2023, then plummeted by 162.87% to -$91.4 million in 2024, then declined by 19.35% to -$111.9 million in 2025.
  • Its EBITDA stands at -$111.9 million for Q3 2025, versus -$102.4 million for Q2 2025 and -$109.8 million for Q1 2025.